AlphaStocks
5.3
Consider Buy

Apellis Pharmaceuticals, Inc. (APLS)

Health Care / Pharmaceuticals

S&P SmallCap 600

$40.40

Below average on several measures. Research carefully.

Consider Buy

Score based on 4 of 5 models — moderate confidence

#489out of 1127 in Health Care

Is Apellis Pharmaceuticals, Inc. a Good Investment in 2026?

Apellis Pharmaceuticals, Inc. (APLS) scores 5.3 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates Apellis Pharmaceuticals, Inc. as Attractive (6/9). However, the Greenblatt Magic Formula model rates it Caution — Bottom half (rank 75%). Apellis Pharmaceuticals, Inc. ranks #489 out of 1127 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE0.7Market Cap5B

Valuation

Trades at 234x earnings — significantly above sector median of 25x. Premium reflects market growth expectations.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

6/9

Buffett

Caution

Business quality & competitive moat

Graham

Neutral

71% above fair value

Lynch

Limited Data

Growth rate vs price (PEG)

Greenblatt

Caution

Bottom half (rank 75%)

Frequently Asked Questions

Is Apellis Pharmaceuticals, Inc. (APLS) a good investment?
Based on AlphaStocks' composite analysis, Apellis Pharmaceuticals, Inc. (APLS) scores 5.3 out of 10, earning a Consider Buy rating. This score is below average, suggesting caution. Trades at 234x earnings — significantly above sector median of 25x. Premium reflects market growth expectations.
What is Apellis Pharmaceuticals, Inc.'s Piotroski F-Score?
Apellis Pharmaceuticals, Inc.'s Piotroski F-Score status is Attractive. The raw score is 6/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is APLS overvalued or undervalued?
A precise fair value estimate is not available for APLS. Trades at 234x earnings — significantly above sector median of 25x. Premium reflects market growth expectations.
How does APLS compare to other Health Care stocks?
Apellis Pharmaceuticals, Inc. ranks #489 out of 1127 stocks in the Health Care sector, placing it in the top 43% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about APLS?
AlphaStocks evaluates APLS using five proven investment models. Piotroski: Attractive; Buffett: Caution; Graham: Neutral; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 5.3/10.

Similar Stocks

PARRFTIAZN

Compare APLS with

APLS vs PARRAPLS vs FTIAPLS vs AZN

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer